Probiotic in Patients With Bile Acid Malabsorption/Diarrhea

Last updated: January 14, 2025
Sponsor: Mayo Clinic
Overall Status: Active - Recruiting

Phase

N/A

Condition

Gastrointestinal Diseases And Disorders

Lactose Intolerance

Hyponatremia

Treatment

Placebo

De Simone formulation probiotic

Clinical Study ID

NCT06609148
24-003006
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to assess effect of the DSF probiotic on fecal bile acid levels in patients with BAM.

Eligibility Criteria

Inclusion

Inclusion criteria:

  • Prior diagnosis of bile acid malabsorption documented in the medical history basedon

  • either serum C4 >52.5ng/mL, or

  • fecal 48h total BA excretion >2337 μmol/48h, or

  • primary BA >5% 48h stool collection or >10% in single stool sample.

  • 7-day stool dairy with an average stool consistency based on the Bristol Stool FormScale, BSFS, with a grade greater than 5. Note: If Inclusion criteria 3 is not met,participants may choose to have their blood drawn clinically to further determineeligibility.

  • For women of childbearing potential

  • A negative urine pregnancy test prior to dispensing the study product

  • Agreement to comply with approved methods of contraception during the wholestudy: unless they meet the criteria of post-menopausal, i.e. 12 months ofspontaneous amenorrhea, women of child-bearing potential, defined as all womenphysiologically capable of becoming pregnant, including women whose career,lifestyle, or sexual orientation precludes intercourse with a male partner,should use one or more of the following acceptable methods of contraceptionthat should be maintained throughout the study:

  • Surgical sterilization

  • Hormonal contraception (implantable, patch, oral, intra-muscular)

  • Intra-uterine device

  • Double barrier method (diaphragm plus condom)

  • At the discretion of the investigator, total abstinence is acceptable incases where age, career, lifestyle, or sexual orientation of the patientensures compliance

Exclusion

Exclusion criteria:

  • Use of oral antibiotics and probiotics within the last 4 weeks.

  • Pregnancy or lactation.

  • Concomitant use of bile acid sequestrants, must stop 10 days before starting 7-daystool dairy and for the duration of the study.

  • History of ileal resection.

  • Diabetes mellitus (type 1)

  • BMI ≥ 40 kg/m^2

  • Diagnosis of gastrointestinal diseases that are associated with inflammation such asinflammatory bowel diseases and celiac diseases or gastrointestinal infection in theprior 4 weeks

  • Any condition or personal circumstance that, in the opinion of the investigator,renders the subject unlikely or unable to comply with the full study protocol orcould interfere with the study assessments

Study Design

Total Participants: 24
Treatment Group(s): 2
Primary Treatment: Placebo
Phase:
Study Start date:
January 02, 2025
Estimated Completion Date:
September 30, 2025

Study Description

In this placebo-controlled trial, the De Simone combination probiotic formulation will be tested in 12 patients in each treatment arm. The patient's will be previously diagnosed with bile acid diarrhea. The objective is to assess the effects of this probiotic on fecal blood low acid levels in patients with bile acid diarrhea. Secondary objectives are to evaluate changes in% primary fecal bile acids in a single stool sample, serum 7 alpha C4, intestinal permeability, stool consistency and frequency, fecal short chain fatty acids, and fecal micro biome composition and diversity

Connect with a study center

  • Mayo Clinic in Rochester

    Rochester, Minnesota 55905
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.